Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SMT C1100 (Utrophin Modulator) in Paediatric Duchenne Muscular Dystrophy
2015-004333-27Phase 2Completed
- Sponsor
- Summit Therapeutics
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ezutromid in Duchenne muscular dystrophy (DMD) (2 cohorts), sponsored by Summit Therapeutics. Started Nov 2015; status: completed.
02
Drugs
ezutromid
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2015-004333-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004333-27.